Cancer Chemother Pharmacol. 2022 Mar 18. doi: 10.1007/s00280-022-04421-7. Online ahead of print.
NO ABSTRACT
PMID:35303141 | DOI:10.1007/s00280-022-04421-7
Categories
Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
